^
    Back
    Association details:
    Biomarker:KIAA1549-BRAF fusion
    Cancer:Glioma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

    Excerpt:
    ...- Group 3: Progressing/Refractory LGG with KIAA1549-BRAF fusion (42 patients)....
    Trial ID:
    TRAM-01
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Neurooncol
    Title:

    Response to trametinib treatment in progressive pediatric low-grade glioma patients

    Published date:
    10/07/2020
    Excerpt:
    In this multi-center retrospective centrally reviewed study, we analyzed 18 patients treated with the MEKi trametinib for progressive pLGG...Alterations detected included 8 KIAA1549:BRAF-fusions, three NF1 alterations, one BRAF V600E mutation and one FGFR1 K654Q mutation....We observed 6 partial responses (PR), 2 minor responses (MR), and 10 stable diseases (SD) as best overall responses....Responses were observed in KIAA1549:BRAF- as well as neurofibromatosis type 1 (NF1)-driven tumors. Median treatment time was 12.5 months (range: 2 to 27 months)....
    DOI:
    10.1007/s11060-020-03640-3